Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, today presented new preclinical data for its lead program, DBXO-1, at the American Association for ...

Target identification is the first and perhaps most critical step in drug discovery and development. Although the human genome contains roughly 20,000 protein-coding genes, only about 4,500 are ...

Neurological disorders represent a highly complex area within medicine, characterized by multifactorial etiologies involving disruptions across numerous ...

Potential disease-modifying targets of Alzheimer’s disease include (but not limited to) amyloid (A), tau (T), neurodegeneration (N), inflammation (I), vascular injury (V), and α-synuclein (S).

Seeking to develop novel medicines for cardiovascular disease, Novartis and ProFound Therapeutics have signed a four-year strategic collaboration. The agreement will allow the partners to combine ...